The project includes the discovery of new drugs that target immunomodulatory pathways involved in cancer and infectious diseases.
In the project, ZoBio’s proprietary fragment screening technology, TINS, will be applied to screen a fragment library of Pyxis Discovery against multiple targets provided by NewLink Genetics, aiming to identify novel lead molecules.